Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer - Archive ouverte HAL Access content directly
Journal Articles OncoImmunology Year : 2022

Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer

(1, 2) , (2, 3) , (2, 3, 4) , (1, 2) , (5) , (5) , (6) , (6) , (7) , (1, 2) , (1, 2) , (2, 3) , (1, 2) , (1, 2)
1
2
3
4
5
6
7

Abstract

Recently, the inhibitory CD94/NKG2A receptor has joined the group of immune checkpoints (ICs) and its expression has been documented in NK cells and CD8+ T lymphocytes in several cancers and some infectious diseases. In colorectal cancer (CRC), we previously reported that NKG2A+ tumor-infiltrating lymphocytes (TILs) are predominantly CD8+ αβ T cells and that CD94 overexpression and/or its ligand HLA-E were associated with a poor prognosis. This study aimed to thoroughly characterize the NKG2A+ CD8+ TIL subpopulation and document the impact of NKG2A on anti-tumor responses in CRC. Our findings highlight new features of this subpopulation: (i) enrichment in colorectal tumors compared to paired normal colonic mucosa, (ii) their character as tissue-resident T cells and their majority terminal exhaustion status, (iii) co-expression of other ICs delineating two subgroups differing mainly in the level of NKG2A expression and the presence of PD-1, (iv) high functional avidity despite reduced proliferative capacity and finally (v) inhibition of anti-tumor reactivity that is overcome by blocking NKG2A. From a clinical point of view, these results open a promising alternative for immunotherapies based on NKG2A blockade in CRC, which could be performed alone or in combination with other IC inhibitors, adoptive cell transfer or therapeutic vaccination.
Fichier principal
Vignette du fichier
2162402X.2022.pdf (4.12 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

inserm-03603232 , version 1 (09-03-2022)

Identifiers

Cite

Kathleen Ducoin, Romain Oger, Linda Bilonda Mutala, Cécile Deleine, Nicolas Jouand, et al.. Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer. OncoImmunology, 2022, 11 (1), ⟨10.1080/2162402X.2022.2046931⟩. ⟨inserm-03603232⟩
38 View
36 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More